


Honokiol DCA

Cat. No.:	HY-124292		
CAS No.:	1620160-42-0		
Molecular Formula:	C ₂₂ H ₁₈ Cl ₄ O ₄		
Molecular Weight:	488.19		
Target:	Androgen Receptor		
Pathway:	Others		
Storage:	Pure form	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (204.84 mM; Need ultrasonic)

Concentration	Solvent	Mass	1 mg	5 mg	10 mg
			1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.0484 mL	10.2419 mL	20.4838 mL
	5 mM		0.4097 mL	2.0484 mL	4.0968 mL
	10 mM		0.2048 mL	1.0242 mL	2.0484 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (5.12 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Honokiol DCA (Honokiol dichloroacetate) is a dichloroacetate analog of Honokiol. Honokiol DCA can inhibit the growth of human prostate cancer cells in vitro and suppress the androgen receptor (AR) protein level^[1].

In Vitro

Honokiol DCA (20-40 μM; 24-48 h) inhibits the viability of LNCaP and C4-2 cells in a dose- and time-dependent manner^[1].
 Honokiol DCA (5-20 μM; 10 days) inhibits clonogenicity of prostate cancer cells^[1].
 Honokiol DCA (20-40 μM; 24-48 h) significantly decreases the level of androgen receptor (AR) and prostate specific antigen (PSA) protein in LNCaP cells^[1].

	Honokiol DCA (40 μ M; 24 h) significantly decreases AR promoter activity in LNCaP and C4-2 cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Honokiol $\square\square\square$ MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Hahm ER, et, al. Honokiol inhibits androgen receptor activity in prostate cancer cells. Prostate. 2014 Apr;74(4):408-20.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA